{"name":"Meiji Pharma","slug":"meiji-pharma","ticker":"4569.T","exchange":"TSE","domain":"meiji-seika-pharma.co.jp","description":"KYORIN Pharmaceutical Co., Ltd., through its subsidiaries, researches and develops, manufactures, and sells ethical and generic drugs in Japan and internationally. The company offers Flutiform, a drug for the treatment of asthma; Lyfuna for cough treatment; Desalex, an antiallergic agent; Beova, and Uritos KYORIN therapeutic agents for overactive bladder; Lasvic, a quinolone synthetic antibacterial agent; Pentasa, a remedy for ulcerative colitis/Crohn's disease; Nasonex and Mometasone KYORIN, which are used as allergic rhinitis therapeutic agents; and Kipres, a leukotriene receptor antagonist anti-bronchial asthma and allergic rhinitis drug. It also provides Mucodyne, a mucoregulating drug; GeneSoC, a real-time PCR system; Rubysta, a disinfectant cleaner; Milton, a disinfectant; over-the-counter drugs; and prescription medicines and quasi-drugs, and diagnostics business. In addition, the company offers subcontracted drug manufacturing services. It has development and commercialization ","hq":"Tokyo, Japan","founded":0,"employees":"","ceo":"","sector":"Anti-Infectives / Generics","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":1404,"stockChange":31,"stockChangePercent":2.26,"marketCap":"$510M","metrics":{"revenue":798180532.1647121,"revenueGrowth":-17.2,"grossMargin":40.9,"rdSpend":0,"netIncome":21797813.621600002,"cash":95340146.70310022,"dividendYield":1.82,"peRatio":8.7,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"ME3241","genericName":"ME3241","slug":"me3241","indication":"Other","status":"phase_1"},{"name":"ME3183","genericName":"ME3183","slug":"me3183","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"ME3241","genericName":"ME3241","slug":"me3241","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"ME3183","genericName":"ME3183","slug":"me3183","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":2,"phaseCounts":{"phase_1":1,"phase_2":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"yahoo_finance","revenue":822393323.8379,"revenuePeriod":"2025-03-31","revenueHistory":[{"period":"2025-03-31","value":822393323.8379},{"period":"2024-03-31","value":755665968.0444001},{"period":"2023-03-31","value":716078407.459},{"period":"2022-03-31","value":667172407.9878}],"grossProfit":376372631.6595,"grossProfitHistory":[{"period":"2025-03-31","value":376372631.6595},{"period":"2024-03-31","value":326385592.1276},{"period":"2023-03-31","value":317149337.57390004},{"period":"2022-03-31","value":312559658.71970004}],"rdSpend":null,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":79453283.5256,"operatingIncomeHistory":[{"period":"2025-03-31","value":79453283.5256},{"period":"2024-03-31","value":39410548.1778},{"period":"2023-03-31","value":32393270.590800002},{"period":"2022-03-31","value":31659933.473600004}],"netIncome":57440526.266200006,"netIncomeHistory":[{"period":"2025-03-31","value":57440526.266200006},{"period":"2024-03-31","value":34612247.557500005},{"period":"2023-03-31","value":29858200.039100002},{"period":"2022-03-31","value":24857599.524400003}],"eps":158.17,"epsHistory":[{"period":"2025-03-31","value":158.17},{"period":"2024-03-31","value":92.74},{"period":"2023-03-31","value":82.44},{"period":"2022-03-31","value":68.62}],"cash":94960834.8057,"cashHistory":[{"period":"2025-03-31","value":94960834.8057},{"period":"2024-03-31","value":87785510.4262},{"period":"2023-03-31","value":122606379.74980001},{"period":"2022-03-31","value":170652604.6698}],"totalAssets":1224028154.8106,"totalLiabilities":362458192.0478,"totalDebt":179787709.2763,"equity":861569962.7628001,"operatingCashflow":22164482.180200003,"operatingCashflowHistory":[{"period":"2025-03-31","value":22164482.180200003},{"period":"2024-03-31","value":9792579.2633},{"period":"2023-03-31","value":12694318.3736},{"period":"2022-03-31","value":40118597.8082}],"capex":-39783538.608100004,"capexHistory":[{"period":"2025-03-31","value":-39783538.608100004},{"period":"2024-03-31","value":-39486410.6382},{"period":"2023-03-31","value":-59457203.3385},{"period":"2022-03-31","value":-17005834.873}],"freeCashflow":-17619056.4279,"dividendsPaid":-19060443.1755,"buybacks":null,"employees":0,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":null,"ebit":null,"ebitda":null,"period":"2025-06-30","revenue":null,"epsBasic":36.57,"netIncome":null,"rdExpense":null,"epsDiluted":36.57,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":1404,"previousClose":1373,"fiftyTwoWeekHigh":1725,"fiftyTwoWeekLow":1359,"fiftyTwoWeekRange":"1359.0 - 1725.0","fiftyDayAverage":1618.62,"twoHundredDayAverage":1555.61,"beta":0,"enterpriseValue":564914214.2235018,"forwardPE":13.4,"priceToBook":0.58,"priceToSales":0.64,"enterpriseToRevenue":0.71,"enterpriseToEbitda":10.94,"pegRatio":0,"ebitda":51656012.446900636,"ebitdaMargin":6.5,"freeCashflow":0,"operatingCashflow":0,"totalDebt":150365724.45349684,"debtToEquity":16.7,"currentRatio":4.6,"returnOnAssets":1.1,"returnOnEquity":2.5,"analystRating":"4.0 - Underperform","recommendationKey":"underperform","numberOfAnalysts":1,"targetMeanPrice":1300,"targetHighPrice":1300,"targetLowPrice":1300,"dividendRate":25,"payoutRatio":0.32,"fiveYearAvgDividendYield":3.28,"exDividendDate":1790640000,"insiderHeldPercent":33,"institutionHeldPercent":23.4,"sharesOutstanding":57446295,"floatShares":36850120,"sharesShort":0,"shortRatio":0,"shortPercentOfFloat":0,"epsTrailing":162.29,"epsForward":105,"revenuePerShare":2197.77,"bookValue":2417.37,"officers":[{"age":58,"name":"Mr. Yutaka  Ogihara","title":"President, CEO & Chairman"},{"age":55,"name":"Mr. Yasuji  Kurose","title":"CFO, CSO, Managing Executive Officer, Director of Corporate Planning & Executive Director"},{"age":null,"name":"Junichi  Ishiyama","title":"Managing Executive Officer, CSO & Head of Drug Discovery Div."},{"age":null,"name":"Kiyoo  Uehara","title":"Managing Executive Officer, CHRO & General Affairs Manager"},{"age":65,"name":"Mr. Michiro  Onota","title":"Exe. Director, Mng. Corp. Off., CMO, Chairman of KYORIN Pharmaceutical Grp. Facilities Co., Ltd"},{"age":null,"name":"Takaaki  Kaji","title":"Senior Managing Executive Officer & Chief Business Development Officer"},{"age":null,"name":"Noriaki  Tamura","title":"Managing Executive Officer, Chief Commercial Officer & GM of Pharmaceutical Sales Division"},{"age":null,"name":"Mr. Kenichi  Nakamura","title":"Corporate Officer & President of KYORIN Pharmaceutical Group Facilities Co., Ltd."}],"industry":"Drug Manufacturers - Specialty & Generic","irWebsite":"","website":"https://www.kyorin-pharm.co.jp","phone":"81 3 6374 9700"}}